Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine
Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC). However, moderate to severe diarrhea and rash (≥ grade 2) are problematic dose limiting toxicities. Since risk may vary over the course of therapy, we developed repeated measures models to...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer US
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173070/ |